NEW YORK (Standard&Poor's) June 22, 2007--Standard&Poor's Ratings Services today said it revised its rating outlook on Bristol-Myers Squibb Co. to stable from negative. At the same time, Standard&Poor's affirmed all of its ratings on Bristol-Myers, including the 'A+' corporate credit rating. "Today's actions reflect the pharmaceutical giant's expected improvement in earnings and cash flow performance, following the favorable U.S. District Court ruling upholding the patent on Bristol-Myers and Sanofi-Aventis SA's cardiovascular drug, Plavix," explained Standard&Poor's credit analyst Arthur Wong. The ratings on New York, N.Y.-based Bristol-Myers reflect the company's diverse product portfolio, the addition of several promising new products over the past several years, and solid financials. Bristol-Myers' EBITDA margin dropped to
